Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03543384
Other study ID # 6810
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 20, 2018
Est. completion date February 2019

Study information

Verified date February 2018
Source University Hospital, Strasbourg, France
Contact Francis VEILLON, MD, PhD
Phone 33 3 88 12 78 65
Email Francis.veillon@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Improved means of positive diagnosis of facial neuritis, the leading cause of peripheral facial palsy


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 2019
Est. primary completion date February 2019
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Age 18-80 years

- Subject giving their consent for their participation

- Patients with neuritis facial (neuritis group) who benefited, between 2009 and 2016, from an MRI of the internal auditory ducts, with gadolinous product injection and on the MRI 3 Tesla

- Patients with a perception deafness, without neuritis sign (control group) who also benefited from an MRI with gadolinous product injection on the MRI 3T with the same protocol.

Exclusion Criteria:

- Refusal to participate in the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Service Imagerie 1 Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence or absence of pathologic enhancement of the facial nerve on the symptomatological side of the T2 sequence (FIESTA-C) 1 hour after the realization of the MRI